Future directions in the management of epithelial ovarian cancer

Future Oncology

Volumn 4, Issue 3, 2008, Pages 403-411

  Blagden, Sarah ^a   Gabra, Hani ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Epithelial ovarian cancer; Histology; Methylation; Ovarian; Resistance; Screening; Symptoms

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBF 1120; CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; IRINOTECAN; MHS 2; OXALIPLATIN; PACLITAXEL; PHENOXODIOL; PLACEBO; PLATINUM COMPLEX; PROTEIN KINASE B INHIBITOR; SORAFENIB; SUNITINIB; TOPOTECAN; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; GENETIC RISK; GYNECOLOGIC SURGERY; HUMAN; INTESTINE PERFORATION; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TRANSVAGINAL ECHOGRAPHY;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 47249164722     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.3.403     Document Type: Review

References (67)

1. Office for National Statistics: Cancer Statistics Registrations Registrations of Cancer Diagnosed in 2004, England. Series MB1, 35 (2007).
2. Welsh Cancer Intelligence and Surveillance Unit: Cancer Incidence in Whales 2000-2004. SA6/01 (2007).
3. Northern Ireland Cancer Registry: Cancer Registrations in Northern Ireland, 2004. (2007).
4. Bray F, Loos AH, Tognazzo S, La Vecchia C: Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int. J. Cancer 113(6), 977-990 (2005).
5. Newby JA, Busby CC, Howard CV, Platt MJ: The cancer incidence temporality index: an index to show temporal changes in the age of onset of overall and specific cancer (England and Wales, 1971-1999). Biomed. Pharmacother. 61(10), 623-630 (2007).
6. Beral V; Million Women Study Collaborators; Bull D, Green J, Reeves G: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574), 1703-1710 (2007).
7. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration: Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630), 1134 (2007).
8. Ahmed FY, Wiltshaw E, A'Hern RP et al.: Natural history and prognosis of untreated Stage I epithelial ovarian carcinoma. J. Clin. Oncol. 14(11), 2968-2975 (1996).
9. Goff BA, Mandel LS, Muntz HG, Melancon CH: Ovarian carcinoma diagnosis. Cancer 89, 2068-2075 (2000).
10. Goff BA, Mandel LS, Drescher CW, Urban N: Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109(2), 221-227 (2007).
11. Okamura H, Katabuchi H, Nitta M, Ohtake H: Structural changes and cell properties of human ovarian surface epithelium in ovarian pathophysiology. Microsc. Res. Tech. 69(6), 469-481 (2006).
12. Powell DE, Puls L, van Nagell J Jr: Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? Hum. Pathol. 23, 846-847 (1992).
13. Puls LE, Powell DE, DePriest PD et al.: Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol. Oncol. 47, 53-57 (1992).
14. Cvetkovic D: Early events in ovarian oncogenesis. Reprod. Biol. Endocrinol. 1, 68 (2003).
15. Menon U: Ovarian cancer: challenges of early detection. Nat. Clin. Pract. Oncol. 4(9), 498-499 (2007).
16. Jacobs IJ, Skates SJ, MacDonald N et al.: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353(9160), 1207-1210 (1999).
17. Menon U, Skates SJ, Lewis S et al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23(31), 7919-7926 (2005).
18. Prat J, Ribé A, Gallardo A: Hereditary ovarian cancer. Hum. Pathol. 36(8), 861-870 (2005).
19. Woodward ER, Sleightholme HV, Considine AM et al.: Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 114(12), 1500-1509 (2007).
20. Fader AN, Rose PG: Role of surgery in ovarian carcinoma. J. Clin. Oncol. 25 (20), 2873-2883 (2007).
21. Bast RC Jr, Badgwell D, Lu Z et al.: New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15 (Suppl. 3); 274-281 (2005).
22. Bast RC Jr, Brewer M, Zou C et al.: Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 174, 91-100 (2007).
23. NICE: Review of the clinical effectiveness and cost effectiveness of paclitaxel for ovarian cancer. Technological Appraisal 55 (2003).
24. van der Burg ME, van Lent M, Buyse M et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 332, 629-634 (1995).
25. Piccart MJ, Bertelsen K, Stuart G et al.: Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int. J. Gynecol. Cancer 13 (Suppl. 2), 144-148 (2003).
26. Muggla FM, Braly PS, Brady MF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18, 106-115 (2000).
27. International Collaborative Ovarian Neoplasm Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360(9332), 505-515 (2002).
28. Armstrong DK, Bundy B, Wenzel L et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (1), 34-43 (2006).
29. Hess V, A Hern R, Nastri N et al.: Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J. Clin. Oncol. 22(6), 1040-1044 (2004).
30. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J. Clin. Oncol. 23(34), 8802-8811 (2005).
31. Winter WE 3rd, Maxwell GL, Man C et al.: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(24), 3621-3627 (2007).
32. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al.: A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br. J. Cancer 94(6), 904-913 (2006).
33. Wamunyokoli FW, Bonome T, Lee JY et al.: Expression profiling of mucinous tumors of the ovary identifies genes of clinicapathologic importance. Clin. Cancer Res. 12(3 Pt 1), 690-700 (2006).
34. Sugiyama T, Yakushiji M, Kamura T et al.: Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63(1), 16-22 (2002).
35. Kita T, Kikuchi Y, Kudoh K et al.: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol. Rep. 7(2), 327-331 (2000).
36. Itamochi H, Kigawa J, Sultana H et al.: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J. Cancer Res. 93(6), 723-728 (2002).
37. Pujade-Lauraine E, Paraiso D, Cure H et al.: Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 829).
38. Blackledge G, Lawton F, Redman C, Kelly K: Response of patients in Phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of Phase II trials. Br. J. Cancer 59(4), 650-653 (1989).
39. NICE: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second line or subsequent treatment of advanced ovarian cancer. Technological Appraisal 91 (2005).
40. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95(1), 1-8 (2004).
41. ten Bokkel Huinink W, Gore M, Carmichael J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15(6), 2183-2193 (1997).
42. O'Byrne KJ, Bliss P, Graham JD et al.: A Phase III study of Doxil/ Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 808).
43. Parmar MK, Ledermann JA, Colombo N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361(9375), 2099-2106 (2003).
44. Pfisterer J, Vergote I, du Bois A, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG: Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15(Suppl. 1), 36-41 (2005).
45. Agarwal R, Kaye SB Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3(7), 502-516 (2003).
46. Furlan D, Carnevali I, Marcomini B et al.: The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin. Cancer Res. 12(11 Pt 1), 3329-3336 (2006).
47. Banno K, Yanokura M, Susumu N et al.: Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol. Rep. 16(6), 1189-1196 (2006).
48. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10(13), 4420-4426 (2004).
49. Samimi G, Fink D, Varki NM et al.: Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res. 6(4), 1415-1421 (2000).
50. Appleton K, Mackay HJ, Judson I et al.: Phase I and pharmacodynamic trial of the DNA methylhransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25(29), 4603-4609 (2007).
51. Fraser M, Leung B, Jahani-Asl A et al.: Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol. 1, 66 (2003).
52. Herst PM, Petersen T, Jerram P, Baty J, Berridge MV: The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem. Pharmacol. 74(11), 1587-1595 (2007).
53. Yang X, Fraser M, Moll UM, Basak A, Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66(6), 3126-3136 (2006).
54. LoPiccoio J, Granville CA, Gills JJ, Dennis PA: Targeting Akt in cancer therapy. Anticancer Drugs 18(8), 861-874 (2007).
55. Blagosklonny MV: How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol. Ther. 4(12), 1307-1310 (2005).
56. Hurwitz H: Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin. Colorectal Cancer 4(Suppl. 2), S62-S68 (2004).
57. Gridelli C, Maione P, Rossi A, de Marinis F: The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist 12(10), 1183-1193 (2007).
58. Quesada AR, Medina MA, Alba E: Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 29(11), 1159-1168 (2007).
59. Han ES, Monk BJ: Bevacizumab in the treatment of ovarian cancer. Expert Rev. Anticancer Ther. 7(10), 1339-1345 (2007).
60. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25(33), 5165-5171 (2007).
61. Cannistra SA, Matulonis UA, Penson RT et al.: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25(33), 5180-5186 (2007).
62. Han ES, Monk BJ: What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol. 105(1), 3-6 (2007).
63. Micha JP, Goldstein BH, Graham C et al.: Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology 71(1-2), 49-53 (2006).
64. Pectasides D, Pectasides E: Maintenance or consolidation therapy in advanced ovarian cancer. Oncology 70(5), 315-324 (2006).
65. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
66. +(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol. Oncol. 108(2), 421-427 (2008).
67. Hylander B, Repasky E, Shrikant P et al.: Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol. Oncol. 101(1), 12-17 (2006).